Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Douglas B. Johnson(Vanderbilt University Medical Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Gregory D. Ayers(Vanderbilt University), Wade T. Iams(Vanderbilt University Medical Center), Charles R. Terry(Vanderbilt University Medical Center), Sarah DeNoble(Massachusetts General Hospital), Marta Colgan(Memorial Sloan Kettering Cancer Center), Marisa Flavin(Memorial Sloan Kettering Cancer Center), Elizabeth Berry(Vanderbilt University Medical Center), A. John Iafrate(Massachusetts General Hospital), Christine M. Lovly(Dana-Farber Cancer Institute), Richard D. Carvajal(Northwell Health), Katherine S. Panageas(Mayo Clinic), Zhiguo Zhao(Vanderbilt University), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 173
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k